美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Militia Long/Short Equity ETF

28.80

-0.2938-1.01%

成交量：1.88万

成交额：54.28万

市值：- -

市盈率：- -

高：28.94

开：28.81

低：28.76

收：29.09

数据加载中...

总览公司新闻公告

4882万元收购一家公司，买断CLDN18.2核心双抗权利

动脉新医药

巨头加码，三抗成为“新风口”

医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗关注国内三抗布局创新药企

甬兴证券有限公司

上半年20起大型药企与中国创新药公司交易！

三抗市场再起波澜！艾伯维19.25亿美元引进一款产品

首个国产原创Bcl-2抑制剂获批上市，创新梯度给药让肿瘤细胞正常凋亡

国产肺癌靶向药成功出海，拉开“源头创新”序幕

【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经

【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌

艾伯维Bcl-2抑制剂VERONA折戟

CPHI制药在线

【中国生物制药(01177.HK)：罗伐昔替尼临床前及临床数据在EHA 2025公布】智通财经APP讯，中国生物制药(0

中国生物制药公告集团在2025年欧洲血液学年会(EHA)上公布了罗伐昔替尼(Rovadicitinib)用于治疗急性移植

100%ORR！强生CD19/CD20双靶CAR-T疗法Ib期数据首次公布

百亿BD，为中国临床质量正名

皮下注射“破局”，肿瘤治疗迎来“分钟级”变革

CPHI制药在线

Bcl-2抑制剂大变局

2025年ASCO中国之声：突破耐药、填补空白科伦博泰生物芦康沙妥珠单抗展现EGFR突变非小细胞肺癌治疗前景

每日经济新闻

ZL-1310针对小细胞肺癌发布更新数据持续展现出强大的抗肿瘤活性及安全性

全球首个！维立志博攻克0成药肿瘤靶点，中国原研药领跑国际

艾伯维挥起拳头

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ORR/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":28.7957,"timestamp":1752868800000,"preClose":29.0895,"halted":0,"volume":18822,"delay":0,"floatShares":3280000,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.2938,"latestTime":"07-18 16:00:00 EDT","open":28.81,"high":28.94,"low":28.76,"amount":542792.1999,"amplitude":0.006188,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":29.0895,"sharesOutstanding":3280000,"nav":28.8,"aum":94464000,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":28.75,"preClose":29.0895,"latestTime":"09:09 EDT","volume":31,"amount":891.25,"timestamp":1752844179206},"volumeRatio":0.38178},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":3280000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.38178,"shares":0,"dividePrice":0,"high":28.94,"amplitude":0.006188,"preClose":29.0895,"low":28.76,"week52Low":25.63,"pbRate":"--","week52High":30.215,"institutionHeld":0,"latestPrice":28.7957,"eps":0,"divideRate":0,"volume":18822,"delay":0,"ttmEps":0,"open":28.81,"prevYearClose":25.88,"prevWeekClose":28.9706,"prevMonthClose":29.28,"prevQuarterClose":29.28,"fiveDayClose":28.9706,"twentyDayClose":28.6963,"sixtyDayClose":28.2935},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552469590","title":"4882万元收购一家公司，买断CLDN18.2核心双抗权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2552469590","media":"动脉新医药","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552469590?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 17:51","pubTimestamp":1752832275,"startTime":"0","endTime":"0","summary":"当前，胃癌CLDN18.2靶点的竞争激烈，除了已上市的zolbetuximab，还有多款ADC产品在研发中。然而，Zolbetuximab主要针对CLDN18.2高表达患者，且在治疗过程中可能引发一些安全性问题，如恶心、呕吐等不良反应。据介绍，此次收购的Bridge Health，持有givastomig需使用的CLDN18.2亲本抗体。这些特性对givastomig成为治疗Claudin 18.2阳性癌症潜在同类最佳双特异性抗体有着核心差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718175353a6b1e0e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718175353a6b1e0e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","BK4526","ORR","BK4535","IMAB"],"gpt_icon":0},{"id":"2552107687","title":"巨头加码，三抗成为“新风口”","url":"https://stock-news.laohu8.com/highlight/detail?id=2552107687","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552107687?lang=zh_cn&edition=fundamental","pubTime":"2025-07-17 16:03","pubTimestamp":1752739384,"startTime":"0","endTime":"0","summary":"ISB 2001在组合中加入CD38，增强对BCMA低表达肿瘤细胞的结合能力，并通过下调抗原表达来阻止癌症产生耐药性，有望成为新一代治疗多发性骨髓瘤的药物。02三抗正在成为新风口单克隆抗体药物因其特异性强、靶向性高和毒副作用小等特点，已在肿瘤、自身性免疫疾病等领域广泛应用。目前，全球已有多款双特异性抗体药物获批上市，适应证主要集中在肿瘤领域。在国内药企中，三特异性抗体同样受到追崇。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717161118a6af3e8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717161118a6af3e8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065731478.USD","IE0031619046.USD","ORR","JNJ","BK4077","CR","BK4006","IE00B66KJ199.SGD","MRK","IE00B19Z4B17.USD","BK4161","PFE","IE00B7SZL793.SGD","CRS","AZN","SLE","IGI"],"gpt_icon":0},{"id":"2552177419","title":"医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗 关注国内三抗布局创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2552177419","media":"甬兴证券有限公司","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552177419?lang=zh_cn&edition=fundamental","pubTime":"2025-07-17 00:00","pubTimestamp":1752681600,"startTime":"0","endTime":"0","summary":"恒生医疗保健指数上涨0.05%，板块整体跑输恒生指数0.88pct。在恒生12 个一级子行业中，医疗保健行业周涨跌幅排名为第9 位。核心观点重磅交易落地，艾伯维引进CD3/BCMA/CD38 管线。投 资建议此次艾伯维引进CD3/BCMA/CD38三抗，进一步点燃了三抗赛道的热情，建议关注国内有三抗布局的企业，如泽璟制药-U、信达生物、神州细胞、基石药业-B、先声药业、汇宇制药-W、恒瑞医药等。风险提示销售不及预期风险，医药政策影响不确定的风险，新药研发失败风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071709103597a911ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071709103597a911ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","IE00BGHQF631.EUR","LU0234570918.USD","LU1861214812.USD","BK4566","LU0648001328.SGD","LU2129689514.USD","LU0345781412.USD","LU0211327993.USD","BK4585","LU0985320562.USD","LU1934455277.USD","LU0320765646.SGD","LU1917777945.USD","LU1064131342.USD","LU0689472784.USD","LU1861219969.SGD","SG9999004303.SGD","LU2264538146.SGD","LU0965508806.USD","SG9999011175.SGD","LU1003077747.HKD","LU0942090050.USD","SG9999001440.SGD","LU2129689431.USD","ABBV","SG9999015986.USD","IE00B4R5TH58.HKD","SGXZ23171101.USD","LU0122379950.USD","LU0868494617.USD","LU0417517546.SGD","LU1988902786.USD","LU1732800096.USD","IE0004445239.USD","BK4152","LU1291159041.SGD","IE00BKVL7J92.USD","BK4588","LU2237443895.HKD","LU1496350502.SGD","LU0310800379.SGD","DE","LU0965509010.AUD","LU1093756168.USD","LU1720051108.HKD","LU2112291526.USD","LU2023251221.USD","ORR","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2551141731","title":"上半年20起大型药企与中国创新药公司交易！","url":"https://stock-news.laohu8.com/highlight/detail?id=2551141731","media":"创鉴汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551141731?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 17:08","pubTimestamp":1752656931,"startTime":"0","endTime":"0","summary":"2025年上半年，大型药企与中国创新药公司之间的交易活动活跃度提高，反映出中国在全球创新药领域的快速崛起和强大吸引力。根据创鉴汇不完全统计，上半年中国创新药企与大型药企共达成20笔交易，披露的交易潜在总金额近300亿美元，其中单笔最高达60.5亿美元，显示出大型药企对中国创新药的高度信心。协议包括首付款8000万美元，潜在交易总额20.1亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716174021a44e69e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716174021a44e69e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2417539215.USD","MSD","BK4080","LU2236285917.USD","SG9999002232.USD","01530","01093","BK4007","BK4599","LU0868494617.USD","LU0889565916.HKD","LU0225284248.USD","SG9999001176.SGD","BK4581","ORR","03692","BK4588","IE00B19Z3B42.SGD","AZN","SGXZ57979304.SGD","LU1066051498.USD","BK4592","SG9999003800.SGD","SG9999001176.USD","LU2462157665.USD","BK4534","LU0306806265.USD","LU2456880835.USD","MRK","BK4550","LU0234572021.USD","LU1894683348.USD","LU0321505868.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","LU1883839398.USD","BK4585","LU0170899867.USD","LU0456855351.SGD","LU1894683264.USD","SG9999011175.SGD","IE00BBT3K403.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0109394709.USD","LU0122379950.USD","PFE","LU0985481810.HKD","IE0002270589.USD","LU0306807586.USD","ADC","SG9999002224.SGD"],"gpt_icon":0},{"id":"2551974502","title":"三抗市场再起波澜！艾伯维19.25亿美元引进一款产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2551974502","media":"制药网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551974502?lang=zh_cn&edition=fundamental","pubTime":"2025-07-14 14:10","pubTimestamp":1752473456,"startTime":"0","endTime":"0","summary":"IGI则将获得7亿美元的预付款，同时还有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，外加基于净销售额的两位数分层特许权使用费，总交易金额最高可达19.25亿美元，足以彰显双方对这款药物的高度信心。根据协议，艾伯维将支付给先声再明一定的预付款，以及最高10.55亿美元的选择性权益付款和里程碑付款，外加大中华区以外地区的销售分成。短短半年内，艾伯维在三抗领域连续出手，足以看出其对这一领域的重视和布局的决心。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507141413469541b2c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507141413469541b2c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1934455194.USD","CRS","SG9999015986.USD","SG9999001440.SGD","LU2065731478.USD","LU2347655156.SGD","PD","LU1496350502.SGD","IE00B7SZL793.SGD","LU1989772840.SGD","LU0203347892.USD","LU0417517546.SGD","LU1989771016.USD","ORR","BK4588","LU2112291526.USD","LU0708994859.HKD","LU2129689514.USD","ABBV","LU1093756325.SGD","LU0256863811.USD","BK4534","LU2237443978.SGD","LU1162221912.USD","LU1244550494.USD","BK4550","LU1291159041.SGD","LU0234570918.USD","LU0320765646.SGD","LU2237443549.SGD","LU0158827948.USD","LU0882574055.USD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU1267930490.SGD","LU1057294990.SGD","LU0738911758.USD","LU1430594728.SGD","LU0795875169.SGD","LU1244550221.USD","LU1496350171.SGD","LU0965509283.SGD","IE00B19Z4B17.USD","LU2133065610.SGD","LU0820561818.USD","TRAE","LU1244550577.SGD","IE00BVYPNW00.USD","PK","LU2237443895.HKD"],"gpt_icon":0},{"id":"2550014956","title":"首个国产原创Bcl-2抑制剂获批上市，创新梯度给药让肿瘤细胞正常凋亡","url":"https://stock-news.laohu8.com/highlight/detail?id=2550014956","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550014956?lang=zh_cn&edition=fundamental","pubTime":"2025-07-11 10:58","pubTimestamp":1752202690,"startTime":"0","endTime":"0","summary":"7月10日，创新药企业亚盛医药宣布，由公司自主研发的新型Bcl-2选择性抑制剂利生妥?（通用名：利沙托克拉）获中国国家药品监督管理局批准附条件上市。这是首个获批上市的国产原创Bcl-2抑制剂，也是全球第二个上市的Bcl-2抑制剂。该药适用于此前已接受包含布鲁顿酪氨酸激酶（BTK）抑制剂在内的系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507113454339762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4097","TLS","ORR"],"gpt_icon":0},{"id":"2549753278","title":"国产肺癌靶向药成功出海，拉开“源头创新”序幕","url":"https://stock-news.laohu8.com/highlight/detail?id=2549753278","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549753278?lang=zh_cn&edition=fundamental","pubTime":"2025-07-07 19:30","pubTimestamp":1751887800,"startTime":"0","endTime":"0","summary":"又一款中国创新药成功获FDA批准，花落迪哲医药。目前，舒沃替尼是全球唯一获批治疗EGFR ex20ins NSCLC的口服小分子靶向药，另外获批的只有强生的生物药Amivantamab。/ 02 /中国药企，不断解锁源头创新舒沃替尼获FDA批准，是中国创新药在全球舞台的又一历史性时刻。JS004是全球首个针对BTLA靶点的单克隆抗体，是一款潜在的“first-in-class”药物。这些药物的研发和获批标志着中国药企在源头创新方面取得了重要突破，展现了中国在全球医药创新领域的潜力和实力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2025-07-07/doc-infesafe7481976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","ORR","ADC","BK4231","BK4080","06978"],"gpt_icon":0},{"id":"2548394331","title":"【基石药业-B(02616.HK)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展】智通财经","url":"https://stock-news.laohu8.com/highlight/detail?id=2548394331","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548394331?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 22:34","pubTimestamp":1751639654,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ORR.AU","PFS","BK4211","III","02616","BK1574","LU1169590202.USD","BK4195","OS","BK4097","BK7095","LU1169589451.USD","BK1161","ORR","BK4006","BK4023","PD","HCC","BK4134"],"gpt_icon":0},{"id":"2546227969","title":"【和誉-B(02256.HK)：和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2546227969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546227969?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 08:26","pubTimestamp":1750897582,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02256","BK4006","09939","PFS","03347","399441","BK1574","ORR","BK1141","BK1583","159938","BK4211","161726","BK4195","HCC","LU2488822045.USD","BK1161","BK1576","BK1515"],"gpt_icon":0},{"id":"2544166696","title":"艾伯维Bcl-2抑制剂VERONA折戟","url":"https://stock-news.laohu8.com/highlight/detail?id=2544166696","media":"CPHI制药在线","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544166696?lang=zh_cn&edition=fundamental","pubTime":"2025-06-19 18:15","pubTimestamp":1750328104,"startTime":"0","endTime":"0","summary":"关注并星标CPHI制药在线Bcl-2抑制剂“水土不服”2025年6月16日，艾伯维宣布Bcl-2抑制剂维奈克拉联合阿扎胞苷一线治疗高危骨髓增生异常综合征的三期临床VERONA宣告失败。这种异质性导致不同患者对Bcl-2抑制剂的敏感性不同，使得药物难以对所有患者都产生理想疗效。Bcl-2抑制剂作用于白血病细胞的凋亡通路，但骨髓基质细胞的保护作用削弱了其疗效，使得白血病细胞难以被有效清除。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619190433a4b27962&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619190433a4b27962&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORR","SG9999015945.SGD","TLS","BK4581","IE00BVYPNV92.GBP","LU0158827948.USD","BK4585","SG9999003800.SGD","OS","LU1003077747.HKD","LU1267930573.SGD","SG9999011175.SGD","LU0310799852.SGD","LU1989771016.USD","LU1244550577.SGD","LU0211327993.USD","IE00BGHQF631.EUR","LU1244550221.USD","LU0203345920.USD","LU0689472784.USD","LU2129689431.USD","ABBV","LU1929549753.HKD","LU1934455863.HKD","LU2087621335.USD","LU2129689514.USD","LU0965509101.SGD","LU0234570918.USD","HR","LU1057294990.SGD","LU2089283258.USD","LU2468319806.SGD","IE00B19Z3581.USD","IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","BK4550","CR","LU1496350171.SGD","IE00BDGV0183.EUR","LU0320765646.SGD","LU0417517546.SGD","BK4161","LU1989772923.USD","LU0128525929.USD","LU0456855351.SGD","LU0949170772.SGD","LU1074936037.SGD","LU1732800096.USD","LU0965509283.SGD"],"gpt_icon":0},{"id":"2544976247","title":"【中国生物制药(01177.HK)：罗伐昔替尼临床前及临床数据在EHA 2025公布】智通财经APP讯，中国生物制药(0","url":"https://stock-news.laohu8.com/highlight/detail?id=2544976247","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544976247?lang=zh_cn&edition=fundamental","pubTime":"2025-06-18 18:42","pubTimestamp":1750243342,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ORR.AU","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","ORR","BK1191","IE00BZ08YT58.USD","BK1515","01177","BK1521","BK7095","BK1589"],"gpt_icon":0},{"id":"2544156976","title":"中国生物制药公告集团在2025年欧洲血液学年会(EHA)上公布了罗伐昔替尼(Rovadicitinib)用于治疗急性移植","url":"https://stock-news.laohu8.com/highlight/detail?id=2544156976","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544156976?lang=zh_cn&edition=fundamental","pubTime":"2025-06-18 18:20","pubTimestamp":1750242031,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["ORR.AU","ROCK","BK1589","BK1521","IE00BZ08YS42.EUR","BK7095","01177","BK1583","BK1191","BK1141","SR","BK4086","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU2065732104.USD","BK1515","03347","ORR","BK1576","BK4197"],"gpt_icon":0},{"id":"2543522626","title":"100%ORR！强生CD19/CD20双靶CAR-T疗法Ib期数据首次公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2543522626","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543522626?lang=zh_cn&edition=fundamental","pubTime":"2025-06-14 11:30","pubTimestamp":1749871855,"startTime":"0","endTime":"0","summary":"6月13日，强生宣布了JNJ-90014496正在进行的Ib期研究的首个临床数据，JNJ-90014496 是一种双靶向抗 CD19/CD20 双特异性自体嵌合抗原受体  T 细胞疗法，正在既往未接受过CAR-T细胞疗法治疗的复发或难治性大 B 细胞淋巴瘤 患者中进行研究。JNJ-4496，是一种双靶向CAR T，旨在结合CD19和 CD20 抗原，这两种细胞表面蛋白通常在恶性B细胞上表达。在接受过既往接受过2线或2线以上治疗的患者的患者中，ORR 为 92%，CRR为75%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250614114543a4a89fb7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250614114543a4a89fb7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JNJ","LU1162221912.USD","IE00BLSP4239.USD","LU0234572021.USD","LU1674673691.USD","IE00BDGV0183.EUR","LU2505996681.GBP","LU2112291526.USD","LU1059921491.USD","LU1221951046.USD","LU0345770993.USD","LU1221951129.SGD","IE00B7SZLL34.SGD","IE00BN8TJ469.HKD","LU1732799900.SGD","BK4022","LU0234570918.USD","LU1585245621.USD","LU1066051811.HKD","IE00BLSP4452.SGD","LU2592432038.USD","LU1894683348.USD","LU0058720904.USD","LU0889566641.SGD","LU0114720955.EUR","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU2089984988.USD","LU1023059063.AUD","BK4504","BK4592","LU1935042991.SGD","LU0203345920.USD","LU1066051498.USD","LU1280957306.USD","BK4568","LU1506573853.SGD","LU0912757837.SGD","ORR","LU1066051225.USD","LU1066053197.SGD","LU0640476718.USD","LU1196500208.SGD","LU0345770308.USD","LU1894683264.USD","LU1430594728.SGD","IE00BBT3K403.USD","IE00B19Z3581.USD","LU1261432733.SGD","CAR"],"gpt_icon":0},{"id":"2542569757","title":"百亿BD，为中国临床质量正名","url":"https://stock-news.laohu8.com/highlight/detail?id=2542569757","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542569757?lang=zh_cn&edition=fundamental","pubTime":"2025-06-12 12:45","pubTimestamp":1749703500,"startTime":"0","endTime":"0","summary":"某种程度上，持续进击的出海潮，也在回应对于中国临床质量的怀疑。日前，辉瑞执行官在回应与三生制药的百亿BD中，也明确透露：中国临床质量是可靠的。辉瑞与三生制药的百亿BD，就为中国临床质量进行了正名。在这样一个百亿BD中，海外MNC对于中国数据的认可，显然也是对中国临床质量的肯定。深度影响全世界不可否认，中国部分临床，确实存在一定乱象，但总体上，质量已经较过去大幅提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-06-12/doc-inezutki8367300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0306807586.USD","LU1894683348.USD","IE00BLSP4239.USD","IE0002270589.USD","SG9999001176.USD","BK4550","PFE","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","LU1066053197.SGD","LU0058720904.USD","LU0321505439.SGD","LU0225284248.USD","LU0225771236.USD","SG9999003800.SGD","LU1057294990.SGD","BK4534","LU1066051498.USD","IE00B19Z3581.USD","LU0868494617.USD","BK1161","LU1894683264.USD","BK1574","BK4533","IE00BLSP4452.SGD","BK4599","06978","BK4568","BK4585","LU0321505868.SGD","BK4581","SG9999001176.SGD","SGXZ57979304.SGD","LU0306806265.USD","LU0170899867.USD","SG9999002232.USD","SG9999011175.SGD","BK4592","LU0234572021.USD","LU0456855351.SGD","LU0985481810.HKD","SG9999013999.USD","LU1023059063.AUD","ORR","IE00BBT3K403.USD","BK4588","LU0289739699.SGD","LU0122379950.USD","LU1883839398.USD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2542319892","title":"皮下注射“破局”，肿瘤治疗迎来“分钟级”变革","url":"https://stock-news.laohu8.com/highlight/detail?id=2542319892","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542319892?lang=zh_cn&edition=fundamental","pubTime":"2025-06-10 18:59","pubTimestamp":1749553190,"startTime":"0","endTime":"0","summary":"6月7日，默沙东皮下注射版PD-1抑制剂帕博利珠单抗正式向中国药监局提交上市申请。这不仅是中国首款申报上市的皮下注射PD-1抗体，更意味着患者未来可能仅需2分钟就能完成抗癌治疗。Halozyme公司认为默沙东皮下注射K药侵犯了其相关专利。除了疗效相当，皮下注射在治疗效率和患者体验方面的优势也十分显著。在患者椅旁停留时间上，皮下注射组较静脉注射组锐减49.7%，从117.2分钟降至59.0分钟。在中国，肿瘤治疗药物的研发竞争也异常激烈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610192102a4a1e09e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610192102a4a1e09e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0211331839.USD","LU0965509283.SGD","BK4516","LU0985320562.USD","LU0265550946.USD","LU2112291526.USD","IE00BLSP4452.SGD","IE00B1BXHZ80.USD","LU2468319806.SGD","LU1934455194.USD","LU0265550359.USD","IE00BN8TJ469.HKD","BK4550","IE00B2B36J28.USD","SG9999015358.SGD","LU1093756325.SGD","SG9999014575.USD","BK4533","LU2089984988.USD","LU1162221912.USD","LU0208291251.USD","ORR","LU0289739699.SGD","SG9999014542.SGD","SGXZ57979304.SGD","SG9999002224.SGD","LU1066051811.HKD","SG9999014559.SGD","LU1066051225.USD","BK4195","LU0320765489.SGD","PFS","LU1699723380.USD","LU1291159041.SGD","LU1035773651.USD","LU1057294990.SGD","SG9999001440.SGD","LU1983299246.USD","LU2324357040.USD","IE00BJJMRZ35.SGD","SG9999014567.USD","LU0238689110.USD","LU0965508806.USD","BK4588","LU0203345920.USD","IE000M9KFDE8.USD","LU1934455863.HKD","01877","LU0203347892.USD","LU0106261372.USD","MRK"],"gpt_icon":0},{"id":"2541580218","title":"Bcl-2抑制剂大变局","url":"https://stock-news.laohu8.com/highlight/detail?id=2541580218","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541580218?lang=zh_cn&edition=fundamental","pubTime":"2025-06-06 17:36","pubTimestamp":1749202607,"startTime":"0","endTime":"0","summary":"亚盛医药的新型Bcl-2选择性抑制剂APG-2575在去年年底已向CDE递交新药上市申请并获纳入优先审评，目前正处于获批倒计时阶段。也正因此，不管是患者还是投资者，对国产Bcl-2抑制剂都有较高期待。越来越多的人已经意识到，Bcl-2抑制剂赛道变局将至。2024年11月，APG-2575递交上市申请，有望成为全球第二款获批的Bcl-2抑制剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1749188367498599045","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4097","BK4085","TLS","DDI","ORR"],"gpt_icon":0},{"id":"2540039959","title":"2025年ASCO中国之声：突破耐药、填补空白 科伦博泰生物芦康沙妥珠单抗展现EGFR突变非小细胞肺癌治疗前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2540039959","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540039959?lang=zh_cn&edition=fundamental","pubTime":"2025-06-04 14:12","pubTimestamp":1749017536,"startTime":"0","endTime":"0","summary":"科伦博泰生物（HK06990）股价再创新高，今日盘中触及363港元/股。消息面上，在近日举行的2025年美国临床肿瘤学会（ASCO）年会上，科伦博泰的TROP2ADC芦康沙妥珠单抗治疗EGFR突变晚期非小细胞肺癌（NSCLC）的多项研究数据重磅公布，其临床价值引发学界广泛关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506043421704414.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506043421704414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["OS","ORR","BK4097","BK4195","BK4211","PFS"],"gpt_icon":0},{"id":"2540759347","title":"ZL-1310针对小细胞肺癌发布更新数据 持续展现出强大的抗肿瘤活性及安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2540759347","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540759347?lang=zh_cn&edition=fundamental","pubTime":"2025-06-02 23:03","pubTimestamp":1748876580,"startTime":"0","endTime":"0","summary":"ZL-1310最新的1期研究数据显示出包括颅内缓解在内的强劲的抗肿瘤活性，且安全性可控，这凸显了其有望成为经治的广泛期小细胞肺癌患者重要治疗选择的潜力。89%的患者肿瘤负荷减轻。\" 再鼎医药将于ASCO会议上举行投资者电话会议及网络直播，重点介绍ZL-1310的最新数据并概述临床开发的后续计划。其中，约三分之二的小细胞肺癌患者在确诊时已经处于广泛期3。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4700776_ZH00776_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4548","BK1588","ADC","BK4139","BK1574","BK4231","TRAE","BK4531","BK4588","LU2488822045.USD","ORR","BK4526","BK4080","09688","BK4585","ZLAB","BK1161"],"gpt_icon":0},{"id":"2540007780","title":"全球首个！维立志博攻克0成药肿瘤靶点，中国原研药领跑国际","url":"https://stock-news.laohu8.com/highlight/detail?id=2540007780","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540007780?lang=zh_cn&edition=fundamental","pubTime":"2025-06-01 09:59","pubTimestamp":1748743157,"startTime":"0","endTime":"0","summary":"维立志博研发的抗PD-L1/4-1BB双抗LBL-024在2025年ASCO舞台再获突破性验证。","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2263243","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["ORR","BK4097","BK1574","OS","BK1161","06978"],"gpt_icon":0},{"id":"2538211551","title":"艾伯维挥起拳头","url":"https://stock-news.laohu8.com/highlight/detail?id=2538211551","media":"新康界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538211551?lang=zh_cn&edition=fundamental","pubTime":"2025-05-25 10:59","pubTimestamp":1748141979,"startTime":"0","endTime":"0","summary":"艾伯维，作为昔日药王的拥有者，面临专利悬崖压境，举起拳头挥向新战场！表1.艾伯维免疫领域核心产品这一颓势直接拖累艾伯维2024年净利润下跌12.03%。表2.艾伯维肿瘤领域核心产品然而，随着百济神州的泽布替尼、阿斯利康的阿卡替尼等二代BTK抑制剂通过“头对头”试验证明更优疗效与安全性，伊布替尼市场份额被快速瓜分。02频繁动刀为了走出“泥潭”，艾伯维在肿瘤领域多次挥刀，转而瞄准自免与神经科学等赛道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525114119a48b5df4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250525114119a48b5df4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BGHQF631.EUR","LU1162221912.USD","IE0009355771.USD","BK4566","LU0861579265.USD","IE00B3PB1722.GBP","LU0122379950.USD","LU2237443382.USD","IE00B19Z3B42.SGD","LU1551013425.SGD","PROC","LU0912757837.SGD","LU0203347892.USD","IE00B4R5TH58.HKD","SG9999015945.SGD","LU0965509101.SGD","LU1983299246.USD","BK4139","ABBV","BK4093","LU0234572021.USD","LU1585245621.USD","LU2129689605.HKD","OS","LU2112291526.USD","SG9999003800.SGD","SG9999015952.SGD","LU1244550221.USD","LU1244550494.USD","LU1989772923.USD","LU2237443895.HKD","LU1244550577.SGD","BK4097","PFS","LU1934455863.HKD","LU0310800379.SGD","LU0949170772.SGD","ORR","IE00BVYPNV92.GBP","LU0820561909.HKD","IE00BDGV0183.EUR","LU0211327993.USD","LU1093756325.SGD","LU2133065610.SGD","IBD","CF","SG9999015986.USD","LU0029864427.USD","IE0002270589.USD","LU2087621335.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}